Oncurious NV is a Belgium-based biotech company focused on developing innovative oncology treatments derived from a series of promising new targets that are designed to enhance T cell activity, migration and influx into resistant tumor sites, boosting the patient's own immune response against cancer. The company's lead immuno-oncology asset is a Treg-depleting asset, targeting a protein specifically expressed on Tregs in the tumor microenvironment. The program is in lead optimization. The company's two other programs are focused on T cell migration and are in the discovery stages.